Changes in platelet function, hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-inflammatory drugs with various cyclooxygenase selectivities in dogs

American Journal of Veterinary Research

Volumn 68, Issue 3, 2007, Pages 251-257

  Brainard, Benjamin M ^a   Meredith, Craig P ^b   Callan, Mary Beth ^b   Budsberg, Steven C ^a   Schofer, Francis S ^b   Driessen, Bernd ^b,c   Otto, Cynthia M ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; ACETYLSALICYLIC ACID; CARPROFEN; DERACOXIB; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; THROMBOXANE B2;

ARTICLE; BLOOD CLOT; BLOOD LEVEL; DOG; DOG DISEASE; FEMALE; HEMOSTASIS; HYPOCOAGULABILITY; MALE; NONHUMAN; OSTEOARTHRITIS; PROSTAGLANDIN BLOOD LEVEL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ANIMALS; ASPIRIN; CARBAZOLES; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DOG DISEASES; DOGS; FEMALE; GENE EXPRESSION REGULATION; HEMOSTASIS; MALE; OSTEOARTHRITIS; PLATELET AGGREGATION; PROSTAGLANDINS; SULFONAMIDES; THIAZINES; THIAZOLES;

ANIMALIA; CANIS FAMILIARIS;

EID: 33947708440     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.3.251     Document Type: Article

References (29)

1. Gierse JK, Staten NR, Casperson GF, et al. Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2. Vet Ther 2002;3:270-280.
2. Jones CJ, Budsberg SC. Physiologic characteristics and clinical importance of the cyclooxygenase isoforms in dogs and cats. J Am Vet Med Assoc 2000;217:721-729.
3. Gambaro G, Perazella MA. Adverse renal effects of anti-inflammatory agents: evaluation of selective and non-selective cyclooxygenase inhibitors. J Intern Med 2003; 253:643-652.
4. Schafer AI. Effects of nonsteroidal anti-inflammatory therapy on platelets. Am J Med 1999;106:25S-36S.
5. Streppa HK, Jones CJ, Budsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res 2002;63:91-94.
6. Kawai S, Nishida S, Kato M, et al. Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human platelets and synovial cells. Eur J Pharmacol 1998;347:87-94.
7. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. New Engl J Med 2001;345:433-442.
8. Patrignani P, Sciulli MG, Manarini S, et al. COX-2 is not involved in thromboxane biosynthesis by activated human platelets. J Physiol Pharmacol 1999;50:661-667.
9. Johnson GJ, Leis LA, Dunlop PC. Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G-protein dysfunction. J Clin Invest 1993;92:2469-2479.
10. Catella-Lawson F, Crofford LJ. Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001;110:28S-32S.
11. Cohen RA, Shepard JT, Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 1983;221:273-274.
12. 2. Science 2002; 296:539-541.
13. Catalfamo JL, Dodds WJ. Isolationofplateletsfromlaboratoryanimals. In: Hawiger J, ed. Methods in enzymology. Vol 169. SanDiegoAcademic Press Inc, 1989;27-34.
14. Donahue SM, Otto CM. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability and fibrinolysis. J Vet Emerg Crit Care 2005;15:9-16.
15. Gurbel PA, Murugesan SR, Lowry DR, et al. Plasma thromboxane and prostacyclin are linearly related and increased in patients presenting with acute myocardial infarction. Prostaglandins Leukot Essent Fatty Acids 1999;61:7-11.
16. Hickford FH, Barr SC, Erb HN. Effect of carprofen on hemostatic variables in dogs. Am J Vet Res 2001;62:1642-1646.
17. McAdam BF, Catella-Lawson F, Mardini IA, et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999;96:272-277.
18. Hwang DH. Species variation in platelet aggregation. In: Long-necker GL, ed. The platelets, physiology and pharmacology. New York: Academic Press Inc, 1985;289-305.
19. Freeman MB, Sicard GA, Valentin LI, et al. The association of in vitro arachidonic acid responsiveness and plasma thromboxane levels with early platelet deposition on the luminal surface of small-diameter grafts. J Vasc Surg 1988;7:554-561.
20. Boudreaux MK, Dillon AR, Ravis WR, et al. Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heart-worm-infected dogs. Am J Vet Res 1991;52:1992-1999.
21. Jackson ML, Searcy GP, Olexson DW. Effect of oral phenylbutazone on whole blood platelet aggregation in the dog. Can J Comp Med 1985;49:271-277.
22. McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005;100:1576-1583.
23. Kazakos GM, Papazoglou LG, Rallis T, et al. Effects of meloxicam on the haemostatic profile of dogs undergoing orthopaedic surgery. Vet Rec 2005;157:444-446.
24. Catella F, Nowak J, Fitzgerald GA. Measurement of renal and non-renal eicosanoid synthesis. Am J Med 1986;81;23-29.
25. 2 and platelet activation. J Appl Phys 1994;76:1548-1552.
26. Shimada Y, Kutsumi Y, Nishio H, et al. Role of platelets in myocardial ischemia-reperfusion injury in dogs. Jpn Circ J 1997;61:241-248.
27. Oei HH, Zoganas HC, Sakane Y, et al. Inhibition of thromboxane biosynthesis in splanchnic ischemia shock. Circ Shock 1986;18:95-106.
28. 2 and prostacyclin production: modification by thromboxane synthetase inhibition. Ann Plast Surg 1988;20:106-111.
29. Durante W, Sunahara FA. Cardiovascular effects of high frequency ventilation - the possible involvement of thromboxane. Prostaglandins Leukot Med 1987;28:127-139.